Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras
Open Access
- 9 August 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 63 (9), 1160-1167
- https://doi.org/10.1093/cid/ciw531
Abstract
Background. Human immunodeficiency virus (HIV)–infected patients coinfected with hepatitis B (HBV) and C (HCV) viruses are at increased risk of end-stage liver disease (ESLD). Whether modern antiretroviral therapy has reduced ESLD risk is unknown. Methods. Twelve clinical cohorts in the United States and Canada participating in the North American AIDS Cohort Collaboration on Research and Design validated ESLD events from 1996 to 2010. ESLD incidence rates and rate ratios according to hepatitis status adjusted for age, sex, race, cohort, time-updated CD4 cell count and HIV RNA were estimated in calendar periods corresponding to major changes in antiretroviral therapy: early (1996–2000), middle (2001–2005), and modern (2006–2010) eras. Results. Among 34 119 HIV-infected adults followed for 129 818 person-years, 380 incident ESLD outcomes occurred. ESLD incidence (per 1000 person-years) was highest in triply infected (11.57) followed by HBV- (8.72) and HCV- (6.10) coinfected vs 1.27 in HIV-monoinfected patients. Adjusted incidence rate ratios (95% confidence intervals) comparing the modern to the early antiretroviral era were 0.95 (.61–1.47) for HCV, 0.95 (.40–2.26) for HBV, and 1.52 (.46–5.02) for triply infected patients. Use of antiretrovirals dually activity against HBV increased over time. However, in the modern era, 35% of HBV-coinfected patients were not receiving tenofovir. There was little use of HCV therapy. Conclusions. Despite increasing use of antiretrovirals, no clear reduction in ESLD risk was observed over 15 years. Treatment with direct-acting antivirals for HCV and wider use of tenofovir-based regimens for HBV should be prioritized for coinfected patients.Keywords
Funding Information
- National Institutes of Health (CDC200-2006-18797)
- Centers for Disease Control and Prevention (90047713)
- Agency for Healthcare Research and Quality (90051652)
- Health Resources and Services Administration (TGF-96118, HCP-97105, CBR-86906, CBR-94036)
- Canadian Institutes of Health Research, Canada; Canadian Institutes of Health Research (CIHR) New Investigator
This publication has 35 references indexed in Scilit:
- Impact of long‐term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis BCancer, 2015
- Liver-related death among HIV/hepatitis C virus-co-infected individualsAIDS, 2015
- Ascertainment and Verification of End-Stage Renal Disease and End-Stage Liver Disease in the North American AIDS Cohort Collaboration on Research and DesignAIDS Research and Treatment, 2015
- Life Expectancy in Patients With Chronic HCV Infection and Cirrhosis Compared With a General PopulationJama-Journal Of The American Medical Association, 2014
- Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaborationThe Lancet, 2014
- Factors Associated With Delayed Hepatitis B Viral Suppression on Tenofovir Among Patients Coinfected With HBV-HIV in the CNICS CohortJAIDS Journal of Acquired Immune Deficiency Syndromes, 2014
- Patterns and Causes of Suboptimal Response to Tenofovir-Based Therapy in Individuals Coinfected With HIV and Hepatitis B VirusClinical Infectious Diseases, 2013
- U.S. Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Loads, and CD4 T-Lymphocyte Cell Counts Among HIV-Infected Persons, 2000 to 2008Annals of Internal Medicine, 2012
- Five‐year on‐treatment efficacy of lamivudine‐, tenofovir‐ and tenofovir + emtricitabine‐based HAART in HBV–HIV‐coinfected patientsJournal of Viral Hepatitis, 2012
- Liver-Related Deaths in Persons Infected With the Human Immunodeficiency VirusArchives of Internal Medicine, 2006